Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
50 hedge funds and large institutions have $283M invested in Mersana Therapeutics in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
19% more funds holding
Funds holding: 42 → 50 (+8)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.05% less ownership
Funds ownership: 3.08% → 3.03% (-0.05%)
6% less capital invested
Capital invested by funds: $302M → $283M (-$19M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$8.26M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$7.36M |
| 3 |
BlackRock
New York
|
+$5.47M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$470K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$399K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$25.6M |
| 2 |
Millennium Management
New York
|
-$955K |
| 3 |
LCM
Laurion Capital Management
New York
|
-$865K |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$346K |
| 5 |
Citigroup
New York
|
-$305K |
MRSN Hedge Fund Activity: Q4 2017 in Review
50 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q4 2017, worth a combined $283M — down 6.3% from $302M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new MRSN positions and 5 closed out — a net gain of 8 holders — while 17 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity International, opening a new position worth an estimated $8.26M. The largest seller was Fidelity Investments, cutting an estimated $25.6M.
- 50 institutional investors held Mersana Therapeutics (MRSN) as of Q4 2017, up from 42 in Q3 2017.
- Funds reported $283M of Mersana Therapeutics stock for Q4 2017, down 6.3% quarter-over-quarter.
- 13 funds opened new Mersana Therapeutics positions in Q4 2017 and 5 closed out, a net change of +8 holders.
- The largest Mersana Therapeutics buyer in Q4 2017 was Fidelity International, an estimated $8.26M added.
- The largest Mersana Therapeutics seller in Q4 2017 was Fidelity Investments, an estimated $25.6M sold.
Based on aggregated 13F filings for Q4 2017.